KEY POINTS
  • Reproductive technology startup Orchid is launching the first commercially available whole genome sequencing test for embryos.
  • The test can identify a child's birth defects, neurodevelopmental disorders, chromosomal abnormalities and pediatric and adult-onset cancers before a pregnancy begins, Orchid said.
  • It said the technology is for couples undergoing IVF, which is a type of treatment for people who are experiencing infertility or are at risk of passing on genetic problems.
Noor Siddiqui, founder and CEO of Orchid, during the web summit for careers during Day 2 of the 2014 Web Summit in Dublin, Ireland, Nov. 5, 2014.

Reproductive technology startup Orchid on Tuesday announced a comprehensive new genetic test that may help many prospective parents across the U.S. breathe a little easier. 

The company is launching the first commercially available whole genome sequencing report for embryos, designed for couples undergoing in vitro fertilization, which is a type of treatment for people experiencing infertility or who are at risk of passing on genetic problems.